Serina Therapeutics to present on POZ-lipid technology at ACS Spring 2025

Serina Therapeutics (SER) announced that Randall Moreadith, CDO, will present new data at the ACS Spring 2025 Meeting and Expo in San Diego, CA. His presentation, titled “A Non-Immunogenic LNP for Gene Delivery: Characterization of Poly(oxazoline) Lipid Nanoparticles,” will highlight findings on the immunogenic profile of Serina’s proprietary POZ-lipid technology. Dr. Moreadith will share data demonstrating that Serina’s POZ-lipid, a key component of lipid nanoparticles, did not trigger an IgM or IgG antibody response following repeat dosing in rats. In contrast, polyethylene glycol-lipid standards, commonly used in current LNP formulations, elicited a strong and boosted antibody response. Anti-PEG antibodies have been implicated as a potential cause of anaphylaxis and other serious adverse events observed in humans receiving PEGylated mRNA vaccines. The absence of an immune response to Serina’s POZ-lipid represents a novel discovery that could enable the development of safer and more effective LNP formulations for gene therapy and RNA-based medicines.